Trial of Poor Performance Status Patients (ToPPS)

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

May 31, 2015

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Pemetrexed

500 mg/m2 IV given over 10 minutes every 21 days

DRUG

Bevacizumab

15 mg/kg IV every 21 days

DRUG

Carboplatin

AUC=5 IV every 21 days

Trial Locations (27)

15232

University of Pittsburgh Medical Center, Pittsburgh

23235

Virginia Cancer Institute, Richmond

29210

South Carolina Oncology Associates, PA, Columbia

29303

Spartanburg Regional Medical Center, Spartanburg

29425

Medical University of South Carolina, Charleston

30501

Northeast Georgia Medical Center, Gainesville

33021

Memorial Regional Cancer Center, Hollywood

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

33180

Aventura Medical Center, Aventura

33308

Holy Cross Hospital, Fort Lauderdale

33435

Collaborative Research Group/ Palm Beach Ins of Hem Onc, Boynton Beach

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

38120

Family Cancer Center, Memphis

43617

Toledo Community Oncology Program, Toledo

45242

Oncology Hematology Care, Cincinnati

46601

Northern Indiana Cancer Research Consortium, South Bend

47802

RHHP/ Hope Cancer Center, Terra Haute

60637

University of Chicago, Chicago

71913

Genesis Cancer Center, Hot Springs

72401

Northeast Arkansas Clinic, Jonesboro

76104

The Center for Cancer and Blood Disorders, Fort Worth

85259

Mayo Clinic - AZ, Scottsdale

91750

Wilshire Oncology Medical Group, LaVerne

07960

Hematology Oncology Associates of Northern NJ, Morristown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER